|
Biomarkers
| | | | | |
|
Baseline NT-proBNP(ng/L){IQR}
|
37
|
846.1{402.4,1488}
|
33
|
1100{474.6,1726}
|
0.306
|
|
Baseline VEGF(pg/mL){IQR}
|
31
|
42.5{23.6,207.2}
|
27
|
37.5{17.4,70.2}
|
0.293
|
|
Baseline MMP-2(ng/mL){IQR}
|
33
|
185.7{172.3,216.9}
|
28
|
185.3{172.1,239.7}
|
0.879
|
|
Baseline MMP-9(ng/mL){IQR}
|
33
|
90{56,185}
|
28
|
102.3{44.2,163.2}
|
0.506
|
|
Baseline TIMP-2(ng/mL){IQR}
|
33
|
64.5{57.6,74.1}
|
28
|
64.3{59.2,70}
|
0.789
|
|
Baseline GALECTIN(ng/L){IQR}
|
33
|
12.8{9.8,15.5}
|
28
|
13{9.2,14.9}
|
0.806
|
|
Age (years)
|
37
|
(62.5 ± 9.1)
|
33
|
(58.8 ± 8.1)
|
0.086
|
|
Female
|
11
|
29.7
|
6
|
18.2
|
0.261
|
|
Race White
|
37
|
100
|
33
|
100
|
.
|
|
Clinical History
| | | | | |
|
Angina
|
8
|
21.6
|
7
|
21.2
|
0.967
|
|
Myocardial infarction
|
1
|
2.7
|
2
|
6.1
|
0.599
|
|
Percutaneous coronary intervention
|
3
|
8.1
|
1
|
3
|
0.616
|
|
Congestive heart failure
|
0
|
0
|
1
|
3
|
0.471
|
|
Hypertension
|
21
|
56.8
|
15
|
45.5
|
0.345
|
|
Diabetes
|
2
|
5.4
|
8
|
24.2
|
0.038
|
|
Insulin use
|
1
|
2.7
|
5
|
15.2
|
0.093
|
|
Hypercholesterolemia
|
15
|
40.5
|
16
|
48.5
|
0.504
|
|
Stroke
|
2
|
5.4
|
2
|
6.1
|
1.000
|
|
Cerebrovascular disease
|
2
|
5.4
|
3
|
9.1
|
0.661
|
|
Peripheral vascular disease
|
1
|
2.7
|
0
|
0
|
1.000
|
|
Current Smoker
|
13
|
35.1
|
12
|
36.4
|
0.915
|
|
Family history CAD
|
12
|
32.4
|
17
|
51.5
|
0.106
|
|
Days from MI to randomization - median {IQR}
|
37
|
22{17–26}
|
33
|
20{14–25}
|
0.135
|
|
Index myocardial infarction
| | | | | |
|
Received thrombolytics
|
1
|
2.7
|
0
|
0
|
1.000
|
|
STE / Q wave / R loss
|
30
|
81.1
|
28
|
84.8
|
0.676
|
|
Killip Class II-IV
|
7
|
18.9
|
4
|
12.1
|
0.522
|
|
Ejection fraction
|
37
|
(46.8 ± 9)
|
33
|
(45.7 ± 10.5)
|
0.652
|
|
Rales
|
0
|
0
|
1
|
3.1
|
0.464
|
|
Clinical measures
| | | | | |
|
Estimated GFR <60 ml/min/1.73 m2
|
5
|
13.5
|
3
|
9.1
|
0.714
|
|
Glucose > =126 mg/dl
|
2
|
5.6
|
6
|
18.2
|
0.140
|
|
BMI (kg/m2)
|
37
|
(26.4 ± 2.8)
|
32
|
(27.2 ± 4.3)
|
0.365
|
|
Heart rate (bpm)
|
37
|
(68.9 ± 9.4)
|
33
|
(69.7 ± 10.3)
|
0.733
|
|
Systolic blood pressure (mmHg)
|
37
|
(119.5 ± 11.4)
|
33
|
(121.4 ± 12.5)
|
0.507
|
|
Angiography
| | | | | |
|
Infarct-related artery (IRA) LAD
|
13
|
35.1
|
6
|
18.2
|
0.240
|
|
Infarct-related artery (IRA) Lcx
|
6
|
16.2
|
5
|
15.2
|
|
Infarct-related artery (IRA) RCA
|
18
|
48.6
|
22
|
66.7
|
|
Angiography - multivessel disease
|
9
|
24.3
|
12
|
37.5
|
0.236
|
|
Collaterals
|
36
|
97.3
|
28
|
87.5
|
0.175
|
|
Medications
| | | | | |
|
Aspirin
|
36
|
97.3
|
32
|
97
|
1.000
|
|
Thienopyridine
|
34
|
91.9
|
8
|
24.2
|
<.001
|
|
Warfarin
|
0
|
0
|
3
|
9.1
|
0.100
|
|
Beta blocker
|
32
|
86.5
|
33
|
100
|
0.056
|
|
Ca blocker
|
1
|
2.7
|
1
|
3
|
1.000
|
|
Lipid lowering agent
|
35
|
94.6
|
33
|
100
|
0.494
|
|
Spironolactone
|
6
|
16.2
|
3
|
9.1
|
0.485
|
|
ACE-Inhibitor or ARB
|
32
|
86.5
|
30
|
90.9
|
0.714
|
